

**Exhibit 18**



September 28, 1995

Naline Bhargava, M.D.  
St. Agnes Medical Center  
3455 Wilkens Avenue  
Baltimore, MD 21223

Dear Dr. Bhargava:

Thank you for referring to the Kennedy - Krieger Institute's clinical trial of the drug Succimer.

She has met criteria for inclusion into the study. She will be given either Succimer or a placebo in conjunction with residential lead clean-up and multivitamin with minerals supplement. The TLC trial will then follow him/her for three to four years with regularly scheduled blood lead monitoring and neurodevelopmental assessments.

Treatment with the study drug was begun on 09/27/95. Each course consists of 26 days of drug, with blood lead levels, complete blood count including neutrophils and serum chemistries sent to our independent physician reviewer and to our data center at Harvard University at day 7, day 28 and day 42. Results from this last visit determines if a second course of drug is required. No child will receive more than three courses of study drug.

Because of the double blind nature of this clinical trial we ask that you refrain from monitoring lead levels **during the treatment phase of the study**, for each participant. If you feel you must check levels, please do not inform the families or us of any results.


As soon as the child is in the follow-up phase of the TLC trial, we will again have lead and other results available to share with you and with the families. Children will be seen every three months for 24 months after treatment, and then every four months until subject age of 72 months or the end of the study. Once treatment is completed, children will be given multivitamins with minerals, and those children who were found to be iron deficient during the enrollment phase will resume iron therapy. In addition to determining lead levels at each

page 2.

visit, families will be seen by a nurse and children will be examined by a pediatrician. Neurodevelopmental assessments will be repeated at periodic intervals.

We will notify you periodically of progress, and when study participation ends. Dr. J. Julian Chisolm, Jr. would be happy to answer any questions or respond to concerns. He may be reached at 550-9035.

Sincerely,

A handwritten signature in cursive script that reads "M Brophy".

Merrill Brophy, Project Manager  
Treatment of Lead Exposed Children  
Clinical Trial